<DOC>
	<DOCNO>NCT00034671</DOCNO>
	<brief_summary>This phase II study conduct : 1. evaluate pharmacokinetics , safety , tolerance , efficacy different dose schedule Posaconazole immunocompromised host variety refractory invasive fungal infection subject require empiric antifungal therapy 2. identify dose schedule provide consistent therapeutic drug exposure patient population .</brief_summary>
	<brief_title>PK/PD Study Posaconazole Empiric Treatment Invasive Fungal Infections Neutropenic Patients Treatment Refractory Invasive Fungal Infections ( Study P01893 )</brief_title>
	<detailed_description>This open-label , randomize , parallel group , study pharmacokinetics , safety , tolerance , efficacy Posaconazole treatment immunocompromised host refractory invasive fungal infection subject require empiric antifungal therapy . The projected number subject plan enrollment 100 evaluable subject . The number plan study sit approximately ten United States approximately eight rest world .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Posaconazole</mesh_term>
	<criteria>A proven , either probable possible invasive fungal infection refractory standard antifungal therapy . Subjects receive &gt; 72 hour systemic empiric antibacterial therapy neutropenic ( &lt; 500 neutrophil per mm3 , fever reach oral temperature &gt; 38c ( &gt; 100.4f ) twice last 48 hour , recurrence fever ( oral temperature , &gt; 38c &gt; 100.4F ) receive broad spectrum antibacterial therapy prior resolution fever antibacterial therapy . Able take oral medication take medication via enteral feed tube .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Aspergillosis , Candidiasis , Mucormycosis , Cryptococcosis</keyword>
	<keyword>Invasive Fungal Infections</keyword>
</DOC>